Angina is a condition in which chest pain occurs when the heart muscle doesn’t get enough oxygen-rich blood. Patients having angina suffer from squeezing and pressure in the chest, and pain in the shoulder, arms, neck, and jaws. Angina is one of the symptoms of cardiovascular disease such as coronary heart disease. In coronary heart disease, plaques build up in the coronary arteries that reduce the flow of oxygen-rich blood which can cause blockage in the blood flow. Angina can be treated by aspirin, nitrates, beta-blockers, statins, calcium channel blockers, and angiotensin-converting enzyme (ACE) inhibitors. Xintong Pharmacy Company is in the process of developing ivabradine as a hyperpolarisation activated cation channel antagonist for the treatment of angina. The University of Alabama at Birmingham is in the process of developing ticagrelor as a Platelet ADP receptor antagonist for the treatment of the disease. Some of the companies having a pipeline of angina include Angionetics Inc., AstraZeneca plc, Heart Metabolics Limited, and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.